New glaucoma treatment for once daily use
Novel Extended Release Glaucoma Therapy for Once Daily Dosing
This study is testing a new eye drop treatment for glaucoma that could lower eye pressure with just one daily application, and it’s designed to work better for people based on their genetics.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tennessee Health Sci Ctr NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project ID | NIH-10817102 on NIH RePORTER |
What this research studies
This research focuses on developing a novel glaucoma therapy that aims to lower intraocular pressure (IOP) effectively with a once-daily topical application. By investigating the genetic factors associated with high IOP, the researchers have identified a specific protein, CACNA2D1, as a target for new medications. The approach involves creating a bioadhesive microemulsion that can deliver a selective blocker of this protein, potentially providing significant IOP reduction and protecting retinal cells. Patients may benefit from a more effective and convenient treatment option that aligns with their genetic profile.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with primary open-angle glaucoma who are currently experiencing elevated intraocular pressure.
Not a fit: Patients with glaucoma who are not responsive to IOP-lowering medications or those with other types of glaucoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with a more effective glaucoma treatment that requires only once-daily dosing.
How similar studies have performed: Other research has shown promise in targeting genetic factors for glaucoma treatment, indicating that this approach may lead to significant advancements.
Where this research is happening
Memphis, United States
- University of Tennessee Health Sci Ctr — Memphis, United States (Active)
Researchers
- Principal investigator: Jablonski, Monica M — University of Tennessee Health Sci Ctr
- Study coordinator: Jablonski, Monica M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.